Hologic Inc. received FDA marketing clearance to use information from the Hologic Discovery Dual Energy X-ray Absorptiometry (DXA) system as a predictor of coronary heart disease, stroke and other forms of cardiovascular disease. The new indication, visualization of Abdominal Aortic Calcification (AAC), targets the No. 1 cause of morbidity and mortality in older women and men — heart disease and stroke.
Discovery measures the two primary diagnostic indicators of osteoporosis — bone mineral density and vertebral fractures. The FDA’s clearance, based on clinical data, means that doctors can use the information from a standard low dose, 10 second Instant Vertebral Assessment (IVA) osteoporosis test, to visualize the presence of AAC, which is associated with cardiovascular disease.
February 09, 2026 
